Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therap... ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. Mehr anzeigen
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -2.97 | -10.2202339986 | 29.06 | 29.71 | 26.09 | 153088 | 28.40998801 | CS |
| 4 | -0.315 | -1.19295587957 | 26.405 | 29.71 | 23.63 | 150845 | 27.07339932 | CS |
| 12 | -1.625 | -5.86325094714 | 27.715 | 30.405 | 23.63 | 151889 | 27.24230499 | CS |
| 26 | 4.46 | 20.6195099399 | 21.63 | 36.37 | 21.22 | 214172 | 26.62108293 | CS |
| 52 | 4.09 | 18.5909090909 | 22 | 36.37 | 14.35 | 166756 | 23.84891057 | CS |
| 156 | 2.09 | 8.70833333333 | 24 | 36.37 | 14.35 | 172969 | 23.64215797 | CS |
| 260 | 2.09 | 8.70833333333 | 24 | 36.37 | 14.35 | 172969 | 23.64215797 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
